Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $68.4K | $-3.07M | $-0.01 |
| 2024 | $28.0K | $-2.91M | $-0.01 |
| 2023 | $19.5K | $-2.90M | $-0.01 |
| 2022 | $36.5K | $-2.47M | $-0.01 |
| 2021 | $14.9K | $-2.53M | $-0.01 |
Social Signal Score
Valuation
RDGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsglobenewswire.com·23h ago·Positive
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing inn
View source ↗ - Newsglobenewswire.com·1d ago·Positive
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, announced it plans to release
View source ↗